Debt ReductionThe dividend cut frees up approximately $200 million per year in cash, which can be re-deployed towards debt repayment.
New Product LaunchVtama has reported good sales figures, and management is confident in its pediatric approval for mild, moderate, and severe disease.
Revenue GrowthOrganon & Co. reiterated revenue guidance of $6.125 billion to $6.325 billion and expects low- to mid-single digit revenue growth post-2025.